Ignite Creation Date:
2024-05-06 @ 12:30 PM
Last Modification Date:
2024-10-26 @ 12:59 PM
Study NCT ID:
NCT03773302
Status:
TERMINATED
Last Update Posted:
2024-05-08
First Post:
2018-12-10
Brief Title:
Phase 3 Study of BGJ398 Oral Infigratinib in First Line Cholangiocarcinoma With FGFR2 Gene FusionsTranslocations
Sponsor:
QED Therapeutics Inc
Organization:
QED Therapeutics Inc
Organization Data
Organization:
QED Therapeutics Inc
Class:
INDUSTRY
Study ID:
QBGJ398-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
QED Therapeutics Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Helsinn Healthcare SA | INDUSTRY |